Puretech Health/PRTC

3.65%
-
1D1W1MYTD1YMAX

About Puretech Health

PureTech Health plc is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company's R&D engine has developed 27 therapeutics and therapeutic candidates, including two (Plenity and EndeavorRx) that have received both United States (US) Food and Drug Administration (FDA) clearance and European marketing authorization. The Company's pipeline includes LYT-100, LYT-200, LYT-300, LYT-310 and LYT-503/IMB-150. LYT-100 (deupirfenidone) is being advanced for the potential treatment of conditions involving inflammation and fibrosis. It is developing LYT-200 for the treatment of metastatic/locally advanced solid tumors that have poor survival rates, including urothelial and head and neck cancers. LYT-300 is an oral prodrug of allopregnanolone, which is being advanced for the potential treatment of anxiety disorders and postpartum depression.

Ticker

PRTC

Sector

Healthcare

Trading on

LSE

Industry

Biotechnology & Drugs

CEO

Bharatt Chowrira

Employees

111

Headquarters

Boston, United States

Puretech Health Metrics

BasicAdvanced
£686.28M
Market cap
-
P/E ratio
-£0.17
EPS
1.16
Beta
-
Dividend rate
£686.28M
1.16027
£3.00
£1.72
545.43K
7.309
3.893
4.979
-34.79%
-5.16%
-8.58%
-5.9%
58.466
1.431
1.338
-45.48%
-315.12%
16.78%

What the Analysts think about Puretech Health

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
135.21% upside
High £6.29
Low £3.73
£2.13
Current price
£5.01
Average price target

Puretech Health Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-806.45% profit margin
QuarterlyAnnual
Q2 23
QoQ growth
Revenue
$3.1M
-63.53%
Net income
$-25M
13.64%
Profit margin
-806.45%
211.59%

Puretech Health Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 1,160%
QuarterlyAnnual
Q2 22
Q2 23
Q4 23
Actual
-$0.08
-$0.32
-
Expected
-$0.20
$0.03
-$0.20
Surprise
-60%
-1,160%
-
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by ICE Data Services and LSEG. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Puretech Health stock?

Puretech Health (PRTC) has a market cap of £686.28M as of April 24, 2024.

What is the P/E ratio for Puretech Health stock?

The price to earnings (P/E) ratio for Puretech Health (PRTC) stock is 0 as of April 24, 2024.

Does Puretech Health stock pay dividends?

No, Puretech Health (PRTC) stock does not pay dividends to its shareholders as of April 24, 2024.

When is the next Puretech Health dividend payment date?

Puretech Health (PRTC) stock does not pay dividends to its shareholders.

What is the beta indicator for Puretech Health?

Puretech Health (PRTC) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Puretech Health stock price target?

The target price for Puretech Health (PRTC) stock is £4.98, which is 133.8% above the current price of £2.13. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Puretech Health stock

Buy or sell Puretech Health stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing